COVERAGE / AZN / Healthcare

ASTRAZENECA PLC

Pharmaceutical Preparations

COVERAGE STATUSACTIVE

DATA THROUGH2025-12-31

RESEARCH REPORTS1

SELECTED FILINGS1

Fundamental matrix

Latest / 2025-12-31 · Prior / 2024-12-31 · USD · Annual periods

Revenue

$58.74bn

Prior / $54.07bn

Change / +8.63%

SOURCE / 2026-02-24

Operating income

$13.74bn

Prior / $10bn

Change / +37.39%

SOURCE / 2026-02-24

Net income

$10.23bn

Prior / $7.04bn

Change / +45.33%

SOURCE / 2026-02-24

Diluted EPS

$6.54

Prior / $4.50

Change / +45.33%

SOURCE / 2026-02-24

Free cash flow

Not available

Prior / Not available

Change / Unavailable

SOURCE / 2026-02-24

Gross margin

81.90%

Prior / 81.12%

Change / +0.77 pp

SOURCE / 2026-02-24

Operating margin

23.40%

Prior / 18.50%

Change / +4.90 pp

SOURCE / 2026-02-24

Return on avg. equity

22.88%

Prior / 17.62%

Change / +5.26 pp

SOURCE / 2026-02-24

Debt / equity

Not available

Prior / Not available

Change / Unavailable

SOURCE / Not available

ROE uses net income divided by average opening/closing equity. FCF = operating cash flow − selected capital expenditure. Debt/equity is unavailable because a verified interest-bearing-debt series is absent; total liabilities are not substituted for debt.

Inspect source tags, dates and accession numbers

{
  "revenue": {
    "start": "2025-01-01",
    "end": "2025-12-31",
    "val": 58739000000,
    "accn": "0001104659-26-019130",
    "fy": 2025,
    "fp": "FY",
    "form": "20-F",
    "filed": "2026-02-24",
    "frame": "CY2025",
    "tag": "ifrs-full:Revenue",
    "unit": "USD"
  },
  "netIncome": {
    "start": "2025-01-01",
    "end": "2025-12-31",
    "val": 10233000000,
    "accn": "0001104659-26-019130",
    "fy": 2025,
    "fp": "FY",
    "form": "20-F",
    "filed": "2026-02-24",
    "frame": "CY2025",
    "tag": "ifrs-full:ProfitLoss",
    "unit": "USD"
  },
  "grossProfit": {
    "start": "2025-01-01",
    "end": "2025-12-31",
    "val": 48106000000,
    "accn": "0001104659-26-019130",
    "fy": 2025,
    "fp": "FY",
    "form": "20-F",
    "filed": "2026-02-24",
    "frame": "CY2025",
    "tag": "ifrs-full:GrossProfit",
    "unit": "USD"
  },
  "operatingIncome": {
    "start": "2025-01-01",
    "end": "2025-12-31",
    "val": 13743000000,
    "accn": "0001104659-26-019130",
    "fy": 2025,
    "fp": "FY",
    "form": "20-F",
    "filed": "2026-02-24",
    "frame": "CY2025",
    "tag": "ifrs-full:ProfitLossFromOperatingActivities",
    "unit": "USD"
  },
  "eps": {
    "start": "2025-01-01",
    "end": "2025-12-31",
    "val": 6.54,
    "accn": "0001104659-26-019130",
    "fy": 2025,
    "fp": "FY",
    "form": "20-F",
    "filed": "2026-02-24",
    "frame": "CY2025",
    "tag": "ifrs-full:DilutedEarningsLossPerShare",
    "unit": "USD/shares"
  },
  "operatingCashFlow": {
    "start": "2025-01-01",
    "end": "2025-12-31",
    "val": 14575000000,
    "accn": "0001104659-26-019130",
    "fy": 2025,
    "fp": "FY",
    "form": "20-F",
    "filed": "2026-02-24",
    "frame": "CY2025",
    "tag": "ifrs-full:CashFlowsFromUsedInOperatingActivities",
    "unit": "USD"
  },
  "totalAssets": {
    "end": "2025-12-31",
    "val": 114074000000,
    "accn": "0001104659-26-019130",
    "fy": 2025,
    "fp": "FY",
    "form": "20-F",
    "filed": "2026-02-24",
    "frame": "CY2025Q4I",
    "tag": "ifrs-full:Assets",
    "unit": "USD"
  },
  "totalLiabilities": {
    "end": "2025-12-31",
    "val": 65355000000,
    "accn": "0001104659-26-019130",
    "fy": 2025,
    "fp": "FY",
    "form": "20-F",
    "filed": "2026-02-24",
    "frame": "CY2025Q4I",
    "tag": "ifrs-full:Liabilities",
    "unit": "USD"
  },
  "shareholdersEquity": {
    "end": "2025-12-31",
    "val": 48667000000,
    "accn": "0001104659-26-019130",
    "fy": 2025,
    "fp": "FY",
    "form": "20-F",
    "filed": "2026-02-24",
    "frame": "CY2025Q4I",
    "tag": "ifrs-full:EquityAttributableToOwnersOfParent",
    "unit": "USD"
  },
  "currentAssets": {
    "end": "2025-12-31",
    "val": 28723000000,
    "accn": "0001104659-26-019130",
    "fy": 2025,
    "fp": "FY",
    "form": "20-F",
    "filed": "2026-02-24",
    "frame": "CY2025Q4I",
    "tag": "ifrs-full:CurrentAssets",
    "unit": "USD"
  },
  "currentLiabilities": {
    "end": "2025-12-31",
    "val": 30617000000,
    "accn": "0001104659-26-019130",
    "fy": 2025,
    "fp": "FY",
    "form": "20-F",
    "filed": "2026-02-24",
    "frame": "CY2025Q4I",
    "tag": "ifrs-full:CurrentLiabilities",
    "unit": "USD"
  }
}

Financial trend system

Annual financial trends are summarized in the accessible table below.

Annual figures / accessible table

Period end	Revenue	Net income	Free cash flow	EPS
2025-12-31	$58.74bn	$10.23bn	Not available	$6.54
2024-12-31	$54.07bn	$7.04bn	Not available	$4.50
2023-12-31	$45.81bn	$5.96bn	Not available	$3.81
2022-12-31	$44.35bn	$3.29bn	Not available	$2.11

Valuation context

Historical snapshot / 2026-09-17. Annual accounting period / 2025-12-31. Not current, TTM or forward valuation.

Dated ratios / eligible same-method sector sample
Measure	Snapshot value	Historical median	Sector median	Peer count
P/E	Unavailable	Unavailable	27.08x	10
P/S	Unavailable	Unavailable	6.63x	10
P/B	Unavailable	Unavailable	7.31x	8
EV / EBITDA	Unavailable	Unavailable	Unavailable	0
FCF yield	Unavailable	Unavailable	3.88%	8

Annual denominators, not TTM or forward. Capitalization-based measures use estimated market capitalization from the dated quote snapshot. ADR/share-basis uncertainty is excluded. No comparable historical-multiple series or EV/EBITDA is available. Sector samples are equal-weight medians of this publication’s eligible covered companies; fiscal periods differ. No fair value or price target is implied.

Source: Not calculated: instrument/share basis requires further review. DAILY-BAR SOURCE ↗

Company & operating context

ASTRAZENECA PLC is an SEC-reporting issuer listed on NYSE under AZN. Its SEC industry description is Pharmaceutical Preparations. This profile organizes annual financial disclosures for research; sector labels are editorial groupings, not GICS classifications.

Drug developers, device manufacturers and care providers depend on distinct clinical, reimbursement and operating economics.

Segment-level revenue is not included in this standardized dataset. Consult the business and segment notes in the linked annual filing for the issuer’s actual reporting segments.

Filing timeline

20-FFILED / 2026-02-24PERIOD / 2025-12-31

AZN filed this 20-F on 2026-02-24 for the reported period 2025-12-31. Reading focus: Product concentration, research investment, utilization, reimbursement and cash generation. This is a metadata-based reading guide; it does not assert that a particular event or risk change occurred in the document.

ORIGINAL SEC DISCLOSURE ↗

Research archive

HR-0020AZNCompany Research

AZN: reading the FY2025 financial structure ↗

ASTRAZENECA PLC

Research abstract

Annual revenue of USD 58.739 billion and net income of USD 10.233 billion for the period ended 2025-12-31.

DATA THROUGH2025-12-312 MIN READPUBLISHED 2026-09-26

Sector context & risk factors

Patent expiry, trial outcomes, reimbursement changes, litigation and acquisition integration.

Product concentration, research investment, utilization, reimbursement and cash generation.

HEALTHCARE SYSTEM ↗

Sources & dates

SEC annual filing · 2025-12-31 ↗Source date 2026-02-24
SEC annual filing · 2024-12-31 ↗Source date 2026-02-24
SEC annual filing · 2023-12-31 ↗Source date 2026-02-24
SEC annual filing · 2022-12-31 ↗Source date 2025-02-18
SEC issuer record ↗Source date 2026-09-18